Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

Table 4 Adverse events

Adverse event	Any grade	%	Grade 3	%
Yellow skin discoloration	25	59	-	-
Fatigue	24	57	1	2
Taste changes	22	52	-	-
Mucositits	21	50	0	0
Hypertension	19	45	7	17
Epigastralgia	15	36	0	0
Nausea/vomiting	14	33	0	0
Anorexia	12	29	2	7
Diarrhea	11	26	0	0
Facial edema	9	21	1	2
Hand and foot syndrome	6	14	0	0
Thyroid function abnormalities	5	12	0	0
Thrombopenia	5	12	1	2
Anemia	4	10	1	2
LVEF reduction*	3	7	1	2
Myalgia	3	7	0	0
Neutropenia	3	7	1	2
Constipation	2	7	0	0
Pneumothorax	1	2	1	2
Hemoptysis	2	7	0	0

There was one grade 5 adverse event (a patient who developed a massive pulmonary embolism, see text).
* Any grade: Reductions in LVEF more than 15% from baseline or LVEF less than 50%. Grade 3: 30–40%.

ISSN: 1471-2407